Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  recurrent adult primary liver cancer
Trial Type:  Treatment
Results 1-25 of 54 for your search:
Start Over
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: HCC-P3-11-01, NCI-2011-03569, NCT01387932
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG-1112, NCI-2012-02057, NCT01730937
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15755, NCI-2016-00158, 2014-005068-13, I4T-MC-JVDE, NCT02435433
A Study of Nivolumab Compared to Sorafenib as a Primary Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-459, NCI-2015-01952, NCT02576509
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-240, NCI-2016-01269, 2015-004567-36, NCT02702401
TRC105 and Sorafenib Tosylate in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0102, NCI-2013-01477, P10766, NCT01306058
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-040, NCI-2013-00864, 2012-001514-42, NCT01658878
Tivozanib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229112, NCI-2013-00756, NCT01835223
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBIHCC-103, NCI-2014-02447, BBI608-503-103HCC, NCT02279719
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15702, NCI-2015-02229, H9H-MC-JBEF, NCT02423343
Enzalutamide with or without Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-279, NCI-2016-00062, NCT02642913
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13665, NCI-2011-00304, H9H-MC-JBAK, NCT01246986
Sorafenib Tosylate following a Liver Transplant in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11-003311, NCI-2012-00911, JCCC-SUPPL-8-2014, ONC-2010-31, NCT01624285
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: D4190C00022, NCI-2016-00207, NCT02519348
Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-224, NCI-2016-00516, 2015-004566-28, NCT02702414
Partial Liver Transplant before Bone Marrow Transplant in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 16 to 65
Trial IDs: j15171, NCI-2016-00821, IRB00080373, CRMS-62535, NCT02702960
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Sorafenib Tosylate and Vorinostat in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-12122, NCI-2010-00185, NCT01075113
Lenalidomide and Sorafenib Tosylate to Treat Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0298, NCI-2011-03283, 1004-05, 1105005453, NCT01348503
Start Over